Skip to main content

Table 1 Baseline clinical characteristics of patients a

From: Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients

Characteristics TCZ users (N= 46) TNFi users (N= 47)
Age (years) 60 (28 to 75) 55 (30 to 76)
Gender 3 males, 43 females 9 males, 38 females
Hb (g/dl) 11.4 (8.9 to 14.4) 11.8 (7.7 to 15.3)
MCV (fl) 91.7 (72.4 to 101.5) 94.2 (79.3 to 104.1)
Ferritin (ng/ml) 81.4 (13.5 to 285.3) 99.2 (9.8 to 398.2)
Fe (μg/dl) 45.8 (9.0 to 120.0) 56.5 (10.0 to 138.0)
CRP (mg/dl) 3.37 (0.05 to 15.24) 2.11 (0.04 to 9.16)
Hepcidin-25 (ng/ml) 28.6 (0.3 to 123) 30.5 (0.4 to 127.4)
Duration of RA (years) 12.54 (1.6 to 43) 8.16 (0.8 to 28)
SJC 7.24 (0 to 24) 5.59 (0 to 23)
TJC 6.74 (0 to 23) 6.54 (1 to 23)
RF (IU/ml) 165.54 (0 to 1,166) 144.24 (0 to 1,625)
DAS28 4.74 (2.00to 7.39) 4.45 (2.33 to 7.23)
  1. aCRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; Fe, serum iron; ferritin, serum ferritin; Hb, hemoglobin; MCV, mean corpuscular volume; RF, rheumatoid factor; SJC, swollen joint count; TCZ, tocilizumab; TJC, tender joint count; TNFi, tumor necrosis factor α inhibitor. All data are means (ranges) unless otherwise specified.